ETNB News and Press, 89bio Inc. From 08/26/22

-Results featured in a late-breaking oral presentation- -Treatment with pegozafermin demonstrated consistent and significant benefit in triglyceride (TG) reduction as well as improvements in liver fat and glycemic control- -Positive data support the advancement into a Ph...

ETNB stock has remained depressed for a long time. Not even solid SHTG data could change that. 89bio's NASH data next year may help. I covered 89bio ( ETNB ) in early 2021, and the stock is down 75% since then, which gives me a reason to take another look at this com...

89bio ( NASDAQ: ETNB ) said it had completed enrollment of 219 patients in the Phase 2b trial of its drug, pegozafermin, to treat NASH. The company expects to report topline data from the trial, Enliven, in the first quarter of 2023. ENLIVEN is a placebo-...

SAN FRANCISCO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has completed en...

89bio press release ( NASDAQ: ETNB ): Q2 GAAP EPS of -$1.23 misses by $0.21 . As of June 30, 2022, 89bio had cash, cash equivalents, and short-term investments of $139.3 million. For further details see: 89bio GAAP EPS of -$1.23 misses by $0.21

- Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase 3 trial expected in the first half of 2023 - - ENTRIGUE data to be presented as a late-breaker at European Society of Cardiology Congress 20...

SVB Leerink has lowered its price target on 89bio ( NASDAQ: ETNB ) from $50 to $29, but has maintained its outperform rating. The SA Quant rating for 89bio is a Hold. 89bio is trading -6.72% . Shares are down -77.79% YTD and -80.20% in the last 12 months. ...

89Bio ( NASDAQ: ETNB ) announced that Deep Track Capital disclosed a 9.99% stake in the company which equals to 4.3M shares ownership. Shares trading 12% higher premarket. For further details see: 89Bio rallies on Deep Track Capital disclosing 10% stake

Gainers: Longeveron ( LGVN ) +16% . Adverum Biotechnologies ( ADVM ) +13% . 89bio ( ETNB ) +12% . Mainz Biomed ( MYNZ ) +11% . Shineco ( SISI ) +8% . Losers: DiaMedica Therapeutics ( DMAC ) -41% . Cytom...

Target Hospitality ( TH ) +22% e xpanded partnership with Leading National Nonprofit Supporting Critical Humanitarian Aid Solutions. Annovis Bio ( ANVS ) +17% wins FDA nod to begin late-stage study for Parkinson's candidate. Grove Collaborative Holdings...